{"id":"NCT02493868","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","officialTitle":"A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-01","primaryCompletion":"2018-02-15","completion":"2018-02-16","firstPosted":"2015-07-10","resultsPosted":"2019-05-21","lastUpdate":"2025-04-29"},"enrollment":719,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Treatment-Resistant"],"interventions":[{"type":"DRUG","name":"Esketamine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Duloxetine (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Escitalopram (Oral antidepressant)","otherNames":[]},{"type":"DRUG","name":"Sertraline (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Venlafaxine Extended Release (XR) (Oral Antidepressant)","otherNames":[]}],"arms":[{"label":"Intranasal Esketamine plus oral antidepressant","type":"EXPERIMENTAL"},{"label":"Placebo Plus Oral Antidepressant","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms in participants with treatment-resistant depression (TRD) who are in stable remission after an induction and optimization course of intranasal esketamine plus an oral antidepressant.","primaryOutcome":{"measure":"Time to Relapse in Participants With Stable Remission (Maintenance Phase)","timeFrame":"Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)","effectByArm":[{"arm":"Intranasal Esketamine + Oral AD","deltaMin":null,"sd":null},{"arm":"Oral AD+ Intranasal Placebo","deltaMin":273,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":155,"countries":["United States","Belgium","Brazil","Canada","Czechia","Estonia","France","Germany","Hungary","Mexico","Poland","Slovakia","Spain","Sweden","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["38557430","37558912","36149841","35022754","34235612","32860422","31166571"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&amp;parentIdentifier=CR107128&amp;attachmentIdentifier=d913e5fa-3636-4665-a11c-7b69d8a8df62&amp;fileName=ESKETINTRD3003_(CR107128)_Additional_results_data_CH.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":437},"commonTop":["Vertigo","Dysgeusia","Dizziness","Headache","Dissociation"]}}